<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04644770</url>
  </required_header>
  <id_info>
    <org_study_id>CR108817</org_study_id>
    <secondary_id>69086420PCR1001</secondary_id>
    <nct_id>NCT04644770</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer</brief_title>
  <official_title>A Phase 1 Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of&#xD;
      JNJ-69086420 in Part 1 (Dose Escalation) and to determine safety and and preliminary signs of&#xD;
      clinical activity at the RP2D(s) in Part 2 (Dose Expansion).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">July 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 23, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 and Part 2: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 2 years and 4 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>Up to 2 years and 4 months</time_frame>
    <description>Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Number of Participants with AEs by Severity</measure>
    <time_frame>Up to 2 years and 4 months</time_frame>
    <description>Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Prostate Specific Antigen (PSA) Response</measure>
    <time_frame>Week 12</time_frame>
    <description>PSA response rate is defined as the percentage of participants with a decline of PSA of 50 percent (%) or more from baseline at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 2 years and 4 months</time_frame>
    <description>ORR is defined as the percentage of participants who have a Partial Response (PR) or better according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 without evidence of bone progression according to Prostate Cancer Working Group 3 (PCWG3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration/Radioactivity (Cmax) of JNJ-69086420</measure>
    <time_frame>Up to 2 years and 4 months</time_frame>
    <description>Cmax is defined as the maximum observed serum concentration/radioactivity of JNJ-69086420.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Serum Concentration/Radioactivity (Tmax) of JNJ-69086420</measure>
    <time_frame>Up to 2 years and 4 months</time_frame>
    <description>Tmax is defined as time to reach maximum observed serum concentration/radioactivity of JNJ-69086420.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-time Curve From Time Zero to t Time (AUC[0-t]) of JNJ-69086420</measure>
    <time_frame>Up to 2 years and 4 months</time_frame>
    <description>AUC(0-t) is defined as the area under the serum concentration-time curve from time zero to t of JNJ-69086420.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-JNJ-69086420 Antibodies</measure>
    <time_frame>Up to 2 years and 4 months</time_frame>
    <description>Number of participants with anti-JNJ-69086420 antibodies will be assessed to evaluate the potential immunogenicity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous (IV) injection of JNJ-69086420 with one or multiple doses. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous (IV) injection of JNJ-69086420 at one of the RP2D(s) determined in Part 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-69086420</intervention_name>
    <description>Participants will receive IV injection of JNJ-69086420.</description>
    <arm_group_label>Part 1: Dose Escalation</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion</arm_group_label>
    <other_name>225Ac-DOTA-h11B6</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic: metastatic castration-resistant prostate cancer (mCRPC) with histologic&#xD;
             confirmation of adenocarcinoma. Adenocarcinoma with small-cell or neuroendocrine&#xD;
             features is allowed&#xD;
&#xD;
          -  Must have had prior exposure to at least one novel androgen receptor (AR) targeted&#xD;
             therapy (example, abiraterone acetate, enzalutamide, apalutamide, darolutamide); prior&#xD;
             taxane or other chemotherapy is acceptable but not required&#xD;
&#xD;
          -  Treatment with other agents for prostate cancer, if received, must have been&#xD;
             discontinued greater than or equal to (&gt;=) 2 weeks prior to first dose of study drug.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Adequate organ functions as reflected in laboratory parameters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Part 1: Prior treatment with radium Xofigo (Ra 223 dichloride), strontium, or samarium&#xD;
             therapy or radioconjugate therapy&#xD;
&#xD;
          -  Known history of myelodysplastic syndrome, leukemia, or hematological malignancy with&#xD;
             features suggestive of myelodysplastic syndrome/acute myeloid leukemia at any&#xD;
             timepoint&#xD;
&#xD;
          -  Toxicity from prior anticancer therapy has not resolved to baseline levels or to Grade&#xD;
             less than or equal to &lt;= 1 (except alopecia, radiation tissue fibrosis, or peripheral&#xD;
             neuropathy)&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to JNJ-69086420 or its excipients&#xD;
             and protein therapeutics&#xD;
&#xD;
          -  Active or chronic hepatitis B or hepatitis C infection.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158-2549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tulane School Of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology Cancer Center and GU Research Network</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108817</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinicaltrials/ transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

